Alkermes ($ALKS) is among the industry's most successful drug delivery firms, boasting licensing deals and royalty streams with drugmakers around the world, in addition to a few in-house treatments in the pipeline. Why, then, has its stock price stayed largely flat? In TheStreet, Nathan Sadeghi-Nejad writes that the company needs to build on its success in drug delivery, perhaps through timely acquisitions of smaller firms. Analysis